Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters

Publication year range
1.
J Pediatr ; 273: 114116, 2024 May 28.
Article in English | MEDLINE | ID: mdl-38815741

ABSTRACT

OBJECTIVE: To assess the effect of treating pulmonary hypertension (PH) in infants younger than 1 year of age with systemic glucocorticoids while using echocardiographic and diagnostic biomarkers as measures of efficacy. STUDY DESIGN: A retrospective chart review was performed on 17 hospitalized infants younger than 1 year of age at St Louis Children's Hospital who received a 5- to 7-day course of systemic glucocorticoid treatment followed by a 3-week taper with no significant intracardiac shunts from January 1, 2017, to December 31, 2021. Quantitative echocardiographic indices for PH, N-terminal pro b-type natriuretic peptide, and/or b-type natriuretic peptide levels were collected before glucocorticoid treatment, after the glucocorticoid burst, and after the 21-day taper. RESULTS: Mean (±SD) gestational age was 32.1 (±5.8) weeks, 5 infants were (29%) concomitantly treated with sildenafil, and 8 were male. Twelve were classified as World Health Organization group 3 PH (71%) and 5 as World Health Organization group 1 PH. There were significant improvements 30 days after glucocorticoid initiation in b-type natriuretic peptide levels (P = .008), PCO2 (P = .03), eccentricity index (P = .005), right ventricular ejection time (P = .04), pulmonary artery acceleration time (P = .002), and pulmonary artery acceleration time-to-right ventricular ejection time ratio (P = .02). Tricuspid regurgitation velocity was not able to be assessed. There were no mortalities during the study timeline. CONCLUSIONS: In our retrospective study, systemic glucocorticoid therapy was well tolerated and appeared to be associated with significant improvement in cardiopulmonary function in infants with PH. Further prospective study in a larger sample is warranted.

2.
Cardiol Young ; 29(3): 286-289, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30678742

ABSTRACT

Paediatric pulmonary hypertension has been described as a secondary complication of multiple diseases and their treatment. Limited information exists about the relationship between pulmonary hypertension and cancer in children. A review of charts was performed in all patients treated for cancer and developed pulmonary hypertension. A total of four patients developed pulmonary hypertension during treatment of cancer. All patients had solid tumors, had echocardiographic evidence of elevated right ventricular pressures, and required intensive care stays. Treatment courses included inhaled and oral pulmonary vasodilators along with systemic steroids. Each had normalisation of echocardiograms and resolution of pulmonary symptoms. Prompt diagnosis of pulmonary hypertension and treatment with pulmonary vasodilators and steroids are considered important measures followed by chemotherapy and radiation regimens.


Subject(s)
Antineoplastic Agents/adverse effects , Hypertension, Pulmonary/etiology , Neoplasms/drug therapy , Pancreatic Neoplasms/therapy , Pulmonary Wedge Pressure/physiology , Acute Disease , Cardiac Catheterization , Child, Preschool , Disease Progression , Echocardiography , Fatal Outcome , Female , Follow-Up Studies , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/drug therapy , Infant , Male , Retrospective Studies , Tomography, X-Ray Computed
4.
J Cell Sci ; 129(5): 898-911, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26769899

ABSTRACT

Neuromuscular junctions (NMJs), the synapses made by motor neurons on muscle fibers, form during embryonic development but undergo substantial remodeling postnatally. Several lines of evidence suggest that α-dystrobrevin, a component of the dystrophin-associated glycoprotein complex (DGC), is a crucial regulator of the remodeling process and that tyrosine phosphorylation of one isoform, α-dystrobrevin-1, is required for its function at synapses. We identified a functionally important phosphorylation site on α-dystrobrevin-1, generated phosphorylation-specific antibodies to it and used them to demonstrate dramatic increases in phosphorylation during the remodeling period, as well as in nerve-dependent regulation in adults. We then identified proteins that bind to this site in a phosphorylation-dependent manner and others that bind to α-dystrobrevin-1 in a phosphorylation-independent manner. They include multiple members of the DGC, as well as α-catulin, liprin-α1, Usp9x, PI3K, Arhgef5 and Grb2. Finally, we show that two interactors, α-catulin (phosphorylation independent) and Grb2 (phosphorylation dependent) are localized to NMJs in vivo, and that they are required for proper organization of neurotransmitter receptors on myotubes.


Subject(s)
Dystrophin-Associated Proteins/metabolism , GRB2 Adaptor Protein/metabolism , Neuromuscular Junction/metabolism , Neuropeptides/metabolism , Receptors, Cholinergic/metabolism , alpha Catenin/metabolism , Animals , Cell Line , HEK293 Cells , Humans , Mice , Mice, Inbred C57BL , Phosphorylation , Protein Interaction Maps , Protein Processing, Post-Translational , Protein Transport , Synaptic Transmission
5.
J Pediatr ; 194: 158-164.e1, 2018 03.
Article in English | MEDLINE | ID: mdl-29198536

ABSTRACT

OBJECTIVE: To describe disease course, histopathology, and outcomes for infants with atypical presentations of alveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV) who underwent bilateral lung transplantation. STUDY DESIGN: We reviewed clinical history, diagnostic studies, explant histology, genetic sequence results, and post-transplant course for 6 infants with atypical ACDMPV who underwent bilateral lung transplantation at St. Louis Children's Hospital. We compared their histology with infants with classic ACDMPV and compared their outcomes with infants transplanted for other indications. RESULTS: In contrast with neonates with classic ACDPMV who present with severe hypoxemia and refractory pulmonary hypertension within hours of birth, none of the infants with atypical ACDMPV presented with progressive neonatal respiratory failure. Three infants had mild neonatal respiratory distress and received nasal cannula oxygen. Three other infants had no respiratory symptoms at birth and presented with hypoxemia and pulmonary hypertension at 2-3 months of age. Bilateral lung transplantation was performed at 4-20 months of age. Unlike in classic ACDMPV, histopathologic findings were not distributed uniformly and were not diffuse. Three subjects had apparent nonmosaic genetic defects involving FOXF1. Two infants had extrapulmonary anomalies (posterior urethral valves, inguinal hernia). Three transplanted children are alive at 5-16 years of age, similar to outcomes for infants transplanted for other indications. Lung explants from infants with atypical ACDMPV demonstrated diagnostic but nonuniform histopathologic findings. CONCLUSIONS: The 1- and 5-year survival rates for infants with atypical ACDMPV are similar to infants transplanted for other indications. Given the clinical and histopathologic spectra, ACDMPV should be considered in infants with hypoxemia and pulmonary hypertension, even beyond the newborn period.


Subject(s)
Lung Transplantation/methods , Persistent Fetal Circulation Syndrome/diagnosis , Pulmonary Alveoli/abnormalities , Female , Forkhead Transcription Factors/genetics , Humans , Infant , Infant, Newborn , Lung/pathology , Male , Mutation , Persistent Fetal Circulation Syndrome/complications , Persistent Fetal Circulation Syndrome/surgery , Pulmonary Alveoli/surgery , Pulmonary Veins/abnormalities , Survival Rate
6.
Pediatr Transplant ; 20(2): 256-70, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26899454

ABSTRACT

The management of decompensating critically ill children with severe PH is extremely challenging and requires a multidisciplinary approach. Unfortunately, even with optimal care, these children might continue to deteriorate and develop inadequate systemic perfusion and at times cardiac arrest secondary to a pulmonary hypertensive crisis. Tools to support these children are limited, and at times, the team should proceed with offering extracorporeal support, especially in newly diagnosed patients who have not benefitted from medical therapy prior to their acute deterioration, in patients with severe pulmonary venous disease and in patients with alveolar capillary dysplasia. Currently, the only approved mode for extracorporeal support in pediatric patients with PH eligible for lung transplantation is ECMO. To decrease the risks associated with ECMO, and offer potential for increased duration of support, extubation, and rehabilitation, we transitioned four small children with refractory PH from ECMO to a device comprising an oxygenator interposed between the PA and LA. This work describes in great detail our experience with this mode of support with emphasis on exclusion criteria, the implantation procedure, and the post-implantation management.


Subject(s)
Extracorporeal Membrane Oxygenation/instrumentation , Hypertension, Pulmonary/therapy , Echocardiography , Equipment Design , Extracorporeal Membrane Oxygenation/methods , Hemodynamics , Humans , Infant , Infant, Newborn , Lung/physiology , Oxygen/chemistry , Perfusion , Practice Guidelines as Topic , Prognosis , Risk , Spectroscopy, Near-Infrared , Steroids/therapeutic use
7.
Clin Genet ; 86(5): 487-91, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24246242

ABSTRACT

Williams-Beuren syndrome (WBS) is a multisystemic genomic disorder typically caused by a recurrent ˜1.5-1.8 Mb deletion on 7q11.23. Atypical deletions can provide important insight into the genotype-phenotype correlations. Here, we report the phenotypic and molecular characterization of a girl with a de novo 81.8 kb deletion in the WBS critical region, which involves the ELN and LIMK1 genes only. The patient presented at 2 months of age with extensive vascular abnormalities, mild facial dysmorphism and delays in her fine motor skills. We discuss potential molecular mechanisms and the role of ELN and LIMK1 in the different phenotypic features. We compare the findings in our patient with previously reported overlapping deletions. The phenotypic variability among these patients suggests that other factors are important in the phenotype and possibly include: position effects related to copy number variation size, variations in the non-deleted alleles, genetic modifiers elsewhere in the genome, or reduced penetrance for specific phenotypes.


Subject(s)
Genetic Association Studies , Williams Syndrome/genetics , Williams Syndrome/pathology , Base Sequence , Chromosome Breakage , Chromosomes, Human/genetics , Comparative Genomic Hybridization , Female , Gene Deletion , Humans , In Situ Hybridization, Fluorescence , Infant , Infant, Newborn , Male , Molecular Sequence Data , Oligonucleotide Array Sequence Analysis , Sequence Analysis, DNA
8.
Am J Med Genet A ; 164A(8): 2013-9, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24842713

ABSTRACT

Position effects due to disruption of distant cis-regulatory regions have been reported for over 40 human gene loci; however, the underlying mechanisms of long-range gene regulation remain largely unknown. We report on two patients with alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) caused by overlapping genomic deletions that included a distant FOXF1 transcriptional enhancer mapping 0.3 Mb upstream to FOXF1 on 16q24.1. In one patient with atypical late-onset ACDMPV, a ∼1.5 Mb deletion removed the proximal 43% of this enhancer, leaving the lung-specific long non-coding RNA (lncRNA) gene LINC01081 intact. In the second patient with severe neonatal-onset ACDMPV, an overlapping ∼194 kb deletion disrupted LINC01081. Both deletions arose de novo on maternal copy of the chromosome 16, supporting the notion that FOXF1 is paternally imprinted in the human lungs. RNAi-mediated knock-down of LINC01081 in normal fetal lung fibroblasts showed that this lncRNA positively regulates FOXF1 transcript level, further indicating that decrease in LINC01081 expression can contribute to development of ACDMPV.


Subject(s)
Enhancer Elements, Genetic , Forkhead Transcription Factors/genetics , Persistent Fetal Circulation Syndrome/genetics , RNA, Long Noncoding/genetics , Adult , Biopsy , Comparative Genomic Hybridization , DNA Mutational Analysis , Female , Gene Expression , Humans , Infant, Newborn , Lung/diagnostic imaging , Lung/pathology , Male , RNA Interference , RNA, Messenger/genetics , Radiography , Sequence Deletion
9.
Child Psychiatry Hum Dev ; 43(1): 1-26, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21701910

ABSTRACT

Pediatric NCCP may be characterized by recurrent pain accompanied by emotional distress and functional impairment. This paper reviews and critiques literature on pediatric noncardiac chest pain (NCCP) and introduces a theoretical conceptualization to guide future study of NCCP in children and adolescents. A developmentally informed biopsychosocial conceptualization of NCCP etiology is proposed based on a synthesis of empirical evidence and clinical observations of pediatric NCCP within the context of relevant findings from the broader pediatric pain and anxiety literature. Multiple factors from biological, psychological, social, familial, and developmental domains are potentially relevant to the etiology of this ailment. This article concludes with directions for future research and clinical implications.


Subject(s)
Chest Pain/psychology , Illness Behavior , Psychophysiologic Disorders/psychology , Social Environment , Somatoform Disorders/psychology , Stress, Psychological/complications , Adolescent , Angina Pectoris/diagnosis , Angina Pectoris/psychology , Anxiety/diagnosis , Anxiety/psychology , Child , Child, Preschool , Cross-Sectional Studies , Depression/diagnosis , Depression/psychology , Diagnosis, Differential , Humans , Psychophysiologic Disorders/diagnosis , Psychophysiologic Disorders/epidemiology , Recurrence , Risk Factors , Somatoform Disorders/diagnosis , Somatoform Disorders/epidemiology , Stress, Psychological/epidemiology , Stress, Psychological/psychology
10.
J Thorac Cardiovasc Surg ; 164(2): 331-341, 2022 08.
Article in English | MEDLINE | ID: mdl-34872760

ABSTRACT

OBJECTIVE: The reversed Potts shunt is an increasingly applied mode of surgical palliation of severe pulmonary hypertension (PH). However, the long-term flow hemodynamic effect of the Potts shunt physiology and desirable long-term hemodynamic end points are not defined. The purpose of this descriptive study was to analyze a series of pediatric patients who underwent surgical Potts shunt as a part of end-stage PH palliation using 4-dimensional (4D)-flow magnetic resonance imaging (MRI) to (1) quantitate the flow through the anastomosis, (2) correlate the shunting pattern with phases of cardiac cycle and PH comorbidities, and (3) describe chronologic changes in shunting pattern. METHODS: This was a 2-center study evaluating 4 patients seen in the Pulmonary Hypertension Clinic at Children's Hospital Colorado who were evaluated and selected to undergo surgical reverse Potts shunt at Washington University School of Medicine and were serially followed using comprehensive imaging including cardiac MRI and 4D-flow MRI. RESULTS: After the procedure, each child underwent 2 4D-flow MRI evaluations. Pulmonary pressure offload was evident in all patients, as demonstrated by positive systolic right-to-left flow across the Potts shunt. All patients experienced some degree of the flow reversal, which occurs primarily in diastole. Interventricular dyssynchrony further contributed to flow reversal across the Potts shunt. Lastly, systemic and pulmonary blood mixing in the descending aorta results in secondary helical flow persisting throughout the diastole. CONCLUSIONS: 4D-flow MRI demonstrates that children who have undergone a Potts shunt for severe PH can experience shunt flow reversal. Cumulatively, this left-to-right pulmonary shunt adds to right ventricular volume overload. We speculate that a valved conduit may decrease the left to right shunting and improve overall cardiac output.


Subject(s)
Hypertension, Pulmonary , Anastomosis, Surgical/methods , Child , Hemodynamics , Humans , Hypertension, Pulmonary/diagnostic imaging , Hypertension, Pulmonary/surgery , Magnetic Resonance Imaging , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/surgery
11.
J Thorac Cardiovasc Surg ; 161(3): 1139-1148, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33454101

ABSTRACT

OBJECTIVE: For children with severe pulmonary hypertension, addition of Potts shunt to a comprehensive palliation strategy might improve the outcomes afforded by medications and delay lung transplantation. METHODS: A prospective analysis was conducted of all children undergoing Potts shunt (first performed in 2013) or bilateral lung transplant for pulmonary hypertension from 1995 to present. RESULTS: A total of 23 children underwent Potts shunt (20 surgical, 3 transcatheter), and 31 children underwent lung transplant. All children with Potts shunt had suprasystemic right ventricle pressures despite maximal medical treatment. In the majority of patients, the Potts shunt was performed through a left thoracotomy approach (90%, 18/20), by direct anastomosis (65%, 13/20), and without the use of extracorporeal support (65%, 13/20). Perioperative outcomes after Potts shunt were superior to lung transplant including mechanical ventilation time (1.3 vs 10.2 days, P = .019), median hospital length of stay (9.8 vs 34 days, P = .012), and overall complication rate (35% [7/20] vs 81% [25/31], P = .003). Risk factors for operative mortality after Potts shunt (20%, 4/20; compared with 6%, 2/31 for lung transplant, P = .195) included preoperative extracorporeal membrane oxygenation and significant right ventricle dysfunction. In midterm follow-up (median 1.8, maximum 6.1 years), patients with Potts shunt had durable equalization of right ventricle/left ventricle pressures and improved functional status. There was no significant survival difference in patients with Potts shunt and patients with lung transplant (P = .258). CONCLUSIONS: Potts shunt is an effective palliation for children with suprasystemic pulmonary hypertension that may become part of a strategy to maximize longevity and functional status for these challenging patients.


Subject(s)
Endovascular Procedures , Hypertension, Pulmonary/surgery , Lung Transplantation , Palliative Care , Vascular Surgical Procedures , Age Factors , Anastomosis, Surgical , Endovascular Procedures/adverse effects , Endovascular Procedures/instrumentation , Endovascular Procedures/mortality , Hemodynamics , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/mortality , Hypertension, Pulmonary/physiopathology , Lung Transplantation/adverse effects , Lung Transplantation/mortality , Prospective Studies , Recovery of Function , Risk Assessment , Risk Factors , Severity of Illness Index , Stents , Time Factors , Treatment Outcome , Vascular Surgical Procedures/adverse effects , Vascular Surgical Procedures/mortality , Ventricular Function, Left , Ventricular Function, Right
12.
J Am Coll Cardiol ; 78(5): 468-477, 2021 08 03.
Article in English | MEDLINE | ID: mdl-34325836

ABSTRACT

BACKGROUND: The placement of a pulmonary-to-systemic arterial shunt in children with severe pulmonary hypertension (PH) has been demonstrated, in relatively small studies, to be an effective palliation for their disease. OBJECTIVES: The aim of this study was to expand upon these earlier findings using an international registry for children with PH who have undergone a shunt procedure. METHODS: Retrospective data were obtained from 110 children with PH who underwent a shunt procedure collected from 13 institutions in Europe and the United States. RESULTS: Seventeen children died in-hospital postprocedure (15%). Of the 93 children successfully discharged home, 18 subsequently died or underwent lung transplantation (20%); the mean follow-up was 3.1 years (range: 25 days to 17 years). The overall 1- and 5-year freedom from death or transplant rates were 77% and 58%, respectively, and 92% and 68% for those discharged home, respectively. Children discharged home had significantly improved World Health Organization functional class (P < 0.001), 6-minute walk distances (P = 0.047) and lower brain natriuretic peptide levels (P < 0.001). Postprocedure, 59% of children were weaned completely from their prostacyclin infusion (P < 0.001). Preprocedural risk factors for dying in-hospital postprocedure included intensive care unit admission (hazard ratio [HR]: 3.2; P = 0.02), mechanical ventilation (HR: 8.3; P < 0.001) and extracorporeal membrane oxygenation (HR: 10.7; P < 0.001). CONCLUSIONS: A pulmonary-to-systemic arterial shunt can provide a child with severe PH significant clinical improvement that is both durable and potentially free from continuous prostacyclin infusion. Five-year survival is comparable to children undergoing lung transplantation for PH. Children with severely decompensated disease requiring aggressive intensive care are not good candidates for the shunt procedure.


Subject(s)
Hypertension, Pulmonary/surgery , Pulmonary Artery/surgery , Adolescent , Anastomosis, Surgical , Child , Child, Preschool , Female , Humans , Infant , Male , Retrospective Studies , Severity of Illness Index , Vascular Surgical Procedures/methods , Young Adult
13.
J Cell Biol ; 160(5): 741-52, 2003 Mar 03.
Article in English | MEDLINE | ID: mdl-12604589

ABSTRACT

alpha-Dystrobrevin (DB), a cytoplasmic component of the dystrophin-glycoprotein complex, is found throughout the sarcolemma of muscle cells. Mice lacking alphaDB exhibit muscular dystrophy, defects in maturation of neuromuscular junctions (NMJs) and, as shown here, abnormal myotendinous junctions (MTJs). In normal muscle, alternative splicing produces two main alphaDB isoforms, alphaDB1 and alphaDB2, with common NH2-terminal but distinct COOH-terminal domains. alphaDB1, whose COOH-terminal extension can be tyrosine phosphorylated, is concentrated at the NMJs and MTJs. alphaDB2, which is not tyrosine phosphorylated, is the predominant isoform in extrajunctional regions, and is also present at NMJs and MTJs. Transgenic expression of either isoform in alphaDB-/- mice prevented muscle fiber degeneration; however, only alphaDB1 completely corrected defects at the NMJs (abnormal acetylcholine receptor patterning, rapid turnover, and low density) and MTJs (shortened junctional folds). Site-directed mutagenesis revealed that the effectiveness of alphaDB1 in stabilizing the NMJ depends in part on its ability to serve as a tyrosine kinase substrate. Thus, alphaDB1 phosphorylation may be a key regulatory point for synaptic remodeling. More generally, alphaDB may play multiple roles in muscle by means of differential distribution of isoforms with distinct signaling or structural properties.


Subject(s)
Cytoskeletal Proteins/deficiency , Cytoskeletal Proteins/genetics , Dystrophin-Associated Proteins , Membrane Proteins/deficiency , Membrane Proteins/genetics , Muscle, Skeletal/metabolism , Neuromuscular Junction/metabolism , Protein Isoforms/metabolism , Sarcolemma/metabolism , Tendons/metabolism , Tyrosine/metabolism , Alternative Splicing/genetics , Animals , Disease Models, Animal , Female , Immunohistochemistry , Male , Mice , Mice, Knockout , Microscopy, Electron , Muscle, Skeletal/innervation , Muscle, Skeletal/ultrastructure , Muscular Dystrophy, Animal/genetics , Muscular Dystrophy, Animal/metabolism , Neuromuscular Junction/ultrastructure , Phosphorylation , Protein Isoforms/genetics , Receptors, Cholinergic/metabolism , Receptors, Cholinergic/ultrastructure , Recombinant Fusion Proteins , Sarcolemma/ultrastructure , Synaptic Membranes/genetics , Synaptic Membranes/metabolism , Tendons/ultrastructure
14.
Neuron ; 34(6): 865-76, 2002 Jun 13.
Article in English | MEDLINE | ID: mdl-12086635

ABSTRACT

We show that fluorescently tagged ligands with high affinity for their targets can be reversibly unbound by focused laser excitation. By sequential unbinding and relabeling with different colors of alpha-bungarotoxin, we selectively labeled adjacent pools of acetylcholine receptors (AChRs) at neuromuscular junctions of adult mice. Timelapse imaging in vivo revealed that synaptic AChRs completely intermingle over approximately 4 days and many extrasynaptic AChRs are incorporated into the synapse each day. In mice that lacked alpha-dystrobrevin, a component of the dystrophin-glycoprotein complex, rates of AChR turnover, and intermingling were increased approximately 4- to 5-fold. These results demonstrate remarkable molecular dynamism underlying macroscopic stability of the postsynaptic membrane, and establish alpha-dystrobrevin as a key control point for regulation of mobility and turnover.


Subject(s)
Dystrophin-Associated Proteins , Fluorescent Dyes/metabolism , Light , Receptors, Neurotransmitter/metabolism , Animals , Binding, Competitive/physiology , Cytoskeletal Proteins/deficiency , Cytoskeletal Proteins/genetics , Female , Ligands , Membrane Proteins/deficiency , Membrane Proteins/genetics , Mice , Microscopy, Fluorescence , Neuromuscular Junction/metabolism , Receptors, Cholinergic/metabolism , Receptors, Cholinergic/physiology , Receptors, Neurotransmitter/physiology
15.
Curr Treat Options Cardiovasc Med ; 20(1): 8, 2018 Feb 20.
Article in English | MEDLINE | ID: mdl-29464391

ABSTRACT

Pulmonary hypertension (PH) is an increasingly recognized problem in children, particularly within tertiary pediatric hospitals. This increase is, in large part, due to ever improving survival among previously fatal conditions, such as extreme prematurity and complicated congenital heart disease. This increased recognition has paralleled burgeoning pharmacologic and interventional PH-specific treatment options. Unfortunately, most PH-specific therapies have not been tested in children with rigorous, randomized, controlled trials. As a result, most treatment of PH in children is based upon expert consensus and practitioners' experience. In this article, we highlight some of the current and recent advances in therapies available for children with PH. The role that a Potts shunt may have in ameliorating severe PH in children is highlighted.

16.
Pulm Circ ; 8(3): 2045894018786696, 2018.
Article in English | MEDLINE | ID: mdl-29916764

ABSTRACT

Pulmonary arteriovenous malformations (PAVMs) often occur in children with hereditary hemorrhagic telangiectasia (HHT). A 14-year longitudinal study of PAVMs in children with HHT was undertaken to assess the prevalence, the clinical impact, and progression of these malformations. This was a retrospective, single-center study from May 2002 to December 2016 of 129 children with HHT diagnosed using Curacao criteria and/or confirmed by genetic testing. Transthoracic contrast echocardiography (TTCE) was the primary screening modality in all patients and PAVMs were diagnosed based on Barzilai criteria. Moderately positive TTCE (Barzilai criteria ≥ 2) was confirmed with subsequent contrast chest CT. New PAVMs were diagnosed with a positive TTCE after an initial negative TTCE. Embolization of PAVMs were performed according to HHT consensus guidelines. Of 129 children with HHT, 76 (59%) were found to have PAVMs. Sixty-seven (88%) were positive for PAVMs on initial screening. Of 63 children without PAVMs on initial screening, 31 were followed for >1 year. Nine of the 31 (29%) developed new PAVMs after initial negative study. Thirty-eight (50%) of the total 76 children with PAVMs had or developed lesions large enough to be treated with embolization. Nine patients with PAVMs initially too small to be treated with embolization, developed progression of disease and ultimately were treated with embolization over time. The majority, 60% (23/38), of the children with large PAVMs had no related clinical symptoms. After embolization, 21% (8/38), of patients underwent repeat interventions. Genetic diagnosis, age, and gender were not associated with risk of having PAVM nor with need for repeat interventions. Nearly 60% of children with HHT develop PAVMs. The risk for new PAVMs to develop, small PAVMs to become large, and previously embolized PAVMs to require further intervention remains throughout childhood. Thus, children with HHT require continued follow-up until adulthood.

17.
Circ Cardiovasc Imaging ; 11(12): e007964, 2018 12.
Article in English | MEDLINE | ID: mdl-30558504

ABSTRACT

BACKGROUND: Pulmonary arterial hypertension is a progressive disease with poor outcomes in children. Right ventricular (RV) function is the most important determinant of the prognosis. Novel application of Potts shunt between left pulmonary artery and descending aorta has been introduced in an attempt to improve the survival. However, the effect of Potts shunt creation on RV function, RV-PA coupling, and survival has not been studied. METHODS AND RESULTS: We evaluated the first 12 consecutive pediatric patients (9 male, median age 11.2 years and weight 32.8 kg) who underwent elective Potts shunt placement for suprasystemic pulmonary arterial hypertension between 2013 and 2017 with echocardiographic indices of RV function, RV work, RV-PA coupling, and pulmonary hemodynamics. Of 12 patients, 1 was excluded because of insufficient preshunt data, 2 died, 1 required lung transplant, and 8 survived for a median of 27 months postshunt. In survivors, WHO functional class significantly ( P=0.01) improved and the majority (5 of 8) came off pulmonary vasodilators at the most recent follow-up. Postshunt RV systolic function improved ( P=0.03), RV afterload decreased ( P <0.01), RV work decreased ( P=0.02), and RV-proximal PA coupling improved ( P<0.01). CONCLUSIONS: This proof of concept study shows that Potts shunt allows improvement in functional status and mid-term transplant-free survival in the majority of the recipients by improvement in RV systolic function and RV-PA coupling in children with suprasystemic pulmonary arterial hypertension.


Subject(s)
Aorta, Thoracic/surgery , Blalock-Taussig Procedure/methods , Hypertension, Pulmonary/surgery , Pulmonary Artery/surgery , Pulmonary Circulation/physiology , Ventricular Function, Right/physiology , Adolescent , Anastomosis, Surgical/methods , Child , Child, Preschool , Echocardiography , Female , Follow-Up Studies , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/physiopathology , Infant , Male , Retrospective Studies , Time Factors , Treatment Outcome
18.
J Neurosci ; 26(11): 2841-51, 2006 Mar 15.
Article in English | MEDLINE | ID: mdl-16540561

ABSTRACT

The dystrobrevins (alphaDB and betaDB) bind directly to dystrophin and are components of a transmembrane dystrophin-glycoprotein complex (DGC) that links the cytoskeleton to extracellular proteins in many tissues. We show here that alphaDB, betaDB, and dystrophin are all concentrated at a discrete subset of inhibitory synapses on the somata and dendrites of cerebellar Purkinje cells. Dystrophin is depleted from these synapses in mice lacking both alphaDB and betaDB, and DBs are depleted from these synapses in mice lacking dystrophin. In dystrophin mutants and alphaDB,betaDB double mutants, the size and number of GABA receptor clusters are decreased at cerebellar inhibitory synapses, and sensorimotor behaviors that reflect cerebellar function are perturbed. Synaptic and behavioral abnormalities are minimal in mice lacking either alphaDB or betaDB. Together, our results show that the DGC is required for proper maturation and function of a subset of inhibitory synapses, that DB is a key component of this DGC, and that interference with this DGC leads to behavioral abnormalities. We suggest that motor deficits in muscular dystrophy patients, which are their cardinal symptoms, may reflect not only peripheral derangements but also CNS defects.


Subject(s)
Cerebellum/physiopathology , Dystrophin-Associated Proteins/physiology , Dystrophin/physiology , Purkinje Cells/physiology , Animals , Ataxia/genetics , Behavior, Animal , Dystrophin/deficiency , Dystrophin/genetics , Dystrophin-Associated Proteins/deficiency , Dystrophin-Associated Proteins/genetics , Genotype , Hippocampus/chemistry , Hippocampus/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred mdx , Mice, Knockout , Multiprotein Complexes , Muscle, Skeletal/chemistry , Muscle, Skeletal/pathology , Muscular Dystrophy, Animal/genetics , Muscular Dystrophy, Animal/physiopathology , Muscular Dystrophy, Animal/psychology , Neuromuscular Junction/chemistry , Neuromuscular Junction/pathology , Prosencephalon/chemistry , Prosencephalon/pathology , Psychomotor Performance , Purkinje Cells/chemistry , Receptor Aggregation , Receptors, GABA-A/deficiency , Receptors, GABA-A/physiology , Retina/chemistry , Retina/physiopathology , Retina/ultrastructure , Synapses/physiology
19.
Case Rep Cardiol ; 2017: 5218321, 2017.
Article in English | MEDLINE | ID: mdl-28785488

ABSTRACT

Congenital systemic-to-pulmonary collateral arteries or major aortopulmonary collaterals are associated with cyanotic congenital heart disease with decreased pulmonary blood flow. Though it is usually associated with congenital heart diseases, there is an increased incidence of isolated acquired aortopulmonary collaterals in premature infants with chronic lung disease. Interestingly, isolated congenital aortopulmonary collaterals can occur without any lung disease, which may cause congestive heart failure and require closure. We present a neonate with an echocardiogram that showed only left-sided heart dilation. Further workup with a CT angiogram demonstrated an anomalous systemic artery from the descending thoracic aorta supplying the left lower lobe. He eventually developed heart failure symptoms and was taken to the catheterization laboratory for closure of the collateral. However, with the collateral being the only source of blood flow to the entire left lower lobe, he required surgical unifocalization. Isolated aortopulmonary collaterals without any other congenital heart disease or lung disease are rare. Our patient is the first reported case to have an isolated aortopulmonary collateral being the sole pulmonary blood supply to an entire lung segment. Due to its rarity, there is still much to learn about the origin and development of these collaterals that possibly developed prenatally.

20.
Ann Thorac Surg ; 101(4): 1539-43, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26518375

ABSTRACT

BACKGROUND: A Potts shunt has been proposed as effective palliative therapy in children with severe pulmonary hypertension (PH) who have suprasystemic right ventricular pressures. METHODS: A retrospective single-center study was performed to assess outcomes in 5 children who underwent a Potts shunt for severe PH. RESULTS: All 5 children were in World Health Organization functional class IV. Only 3 children were classified as having idiopathic pulmonary arterial PH. Preoperatively, 4 children were receiving intravenous prostacyclins, and 3 were placed on intravenous inotropes for acute right-side heart failure. Three children were potential lung transplant candidates. All but 1 child had evidence for suprasystemic right heart pressures immediately before their operation. All 5 children survived the procedure without significant complications. Four of the 5 children were successfully discharged from the hospital and have had sustained clinical improvement with follow-up ranging from approximately 5 to 16 months. The child who did not have suprasystemic right-side heart pressures before the operation did not benefit from the Potts shunt. CONCLUSIONS: The Potts shunt can be an effective palliation for children with severe PH. Our results further suggest that (1) a Potts shunt should be considered early in a child's clinical course, before right ventricular deterioration develops; (2) a Potts shunt should be considered in any child with severe, intractable PH regardless of etiology; (3) one might consider a Potts shunt in lieu of intravenous prostacyclins; and (4) a Potts shunt should be considered before lung transplantation and does not preclude future transplantation candidacy.


Subject(s)
Blalock-Taussig Procedure/methods , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/surgery , Palliative Care/methods , Adolescent , Cardiac Catheterization/methods , Child , Child, Preschool , Echocardiography, Doppler/methods , Female , Follow-Up Studies , Humans , Male , Patient Safety , Retrospective Studies , Risk Assessment , Sampling Studies , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL